Significant declines in antibody levels or concerning numbers of breakthrough infections in vaccinated individuals should spur consideration for booster doses of currently authorized COVID-19 vaccines, members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices said.
At a 23 June meeting, ACIP was asked what data would be needed to move forward with booster recommendations, and whether the risk of disease is enough to warrant a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?